Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc.

CGEM·NASDAQ

$15.21

-0.85%
HealthcareMedical - Pharmaceuticals

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

At a Glance

Live Snapshot
Market Cap$934.78M
EPS-3.7200
P/E Ratio-4.09
Earnings Date08/06/2026

cgem

Total Current Assets

Last Annual Value

386.76M

3-Year CAGR

-7%

5-Year CAGR

13%

10-Year CAGR

27%

Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc. Competitors Analysis of Total Current Assets

CGEM · NASDAQ
CompanyTotal Current Assets
CAGR 3Y
CAGR 5Y
CAGR 10Y
386.76M
-7.0%5.5%N/A 
641.80M
-0.8%3.0%N/A
CBLL logo
CeriBell, Inc.
NASDAQ:CBLL
186.72M
53.2%N/AN/A
EHAB logo
Enhabit, Inc.
NYSE:EHAB
205.60M
-0.7%2.8%N/A
454.26M
42.1%44.5%16.7%
190.54M
-26.4%-14.4%N/A
235.24M
13.3%4.0%N/A
215.67M
-0.3%-2.8%13.6%
Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc. Fair Value Envelope

CGEM · NASDAQ

Our analysis suggests that CGEM has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $15.21, this represents a potential HIDDEN relative to our calculated worth for Cullinan Therapeutics, Inc..

Intrinsic Value
Current Price: $15.21